文献速递浆细胞疾病造血干细胞移植与细胞治疗

高危初诊多发性骨髓瘤自体干细胞移植后序贯抗CD19与抗BCMA CAR-T细胞输注并来那度胺维持治疗

Anti-CD19 and anti-BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma.
PubMed 文献 · Am J Hematol · 2022-02-09

这项单臂探索性临床试验首次评估10例高危初诊多发性骨髓瘤患者自体干细胞移植后序贯输注抗CD19与抗BCMA CAR-T细胞、继以来那度胺维持治疗的安全性与疗效;治疗总体耐受良好,全部患者发生细胞因子释放综合征(1级5例、2级5例),未见神经毒性,总缓解率100%,中位随访42个月时7例持续微小残留病阴性超过2年,中位无进展生存期与总生存期均未达到。

要点

  • 10例高危初诊多发性骨髓瘤患者接受自体干细胞移植后序贯抗CD19与抗BCMA CAR-T细胞输注及来那度胺维持治疗。
  • 全部患者发生细胞因子释放综合征(1级5例、2级5例),CAR-T输注后未见神经毒性。
  • 总缓解率100%,最佳疗效为严格完全缓解90%、完全缓解10%;中位随访42个月时7例持续微小残留病阴性超过2年。

核心结论

  • 尽管样本量小且为单臂研究缺乏对照,观察到的临床获益值得开展随机对照试验。

研究设计与样本

  • 单臂探索性临床试验,纳入10例高危初诊多发性骨髓瘤患者,评估自体干细胞移植后序贯抗CD19与抗BCMA CAR-T细胞输注并来那度胺维持治疗的安全性与疗效。

主要发现

  • 治疗总体耐受良好,血液学毒性是最常见的3级或以上不良事件。
  • 全部患者发生细胞因子释放综合征,1级5例(50%)、2级5例(50%);CAR-T细胞输注后未观察到神经毒性。
  • 总缓解率100%,最佳疗效为严格完全缓解90%、完全缓解10%。
  • 中位随访42(36-49)个月,10例中7例(70%)持续微小残留病阴性超过2年。
  • 中位无进展生存期与总生存期均未达到。

局限性

  • 样本量小。
  • 单臂研究缺乏对照。
  • 观察到的临床获益值得开展随机对照试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Few prospective studies have examined posttransplant chimeric antigen receptor (CAR) T cell infusion as candidates for front-line consolidation therapy for high-risk multiple myeloma (MM) patients. This single-arm exploratory clinical trial is the first to evaluate the safety and efficacy of sequential anti-CD19 and anti-BCMA CAR-T cell infusion, followed by lenalidomide maintenance after autologous stem cell transplantation (ASCT), in 10 high-risk newly diagnosed multiple myeloma (NDMM) patients. The treatment was generally well tolerated, with hematologic toxicities being the most common grade 3 or higher adverse events. All patients had cytokine release syndrome (CRS), which was grade 1 in 5 patients (50%) and grade 2 in 5 patients (50%). No neurotoxicity was observed after CAR-T cell infusion. The overall response rate was 100%, with the best response being 90% for a stringent complete response (sCR), and 10% for a complete response (CR). At a median follow-up of 42 (36-49) months, seven (70%) of 10 patients showed sustained minimal residual disease (MRD) negativity for more than 2 years. The median progression-free survival (PFS) and overall survival (OS) were not reached. Although the sample size was small and there was a lack of control in this single-arm study, the clinical benefits observed warrant ongoing randomized controlled trials.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Shi X, Yan L, Shang J, et al. Anti-CD19 and anti-BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma. Am J Hematol. 2022. PMID: 35114022. doi:10.1002/ajh.26486

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。